Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

impairment charges -- 2,305 297 8,744 Total operating expenses 18,130 33,364 83,059 159,932 Loss from operations (13,862) (20,762) (73,010) (91,904) Investment and other income (expense), net (780) 4,389 781 9,887 Loss before income taxes (14,642) (16,373) (72,229) (82,017) Income tax benefit (expense) 693 (1,122) 2,023 (498) Net loss $(13,949) $(17,495) $(70,206) $(82,515) Basic and diluted net loss per share: ($0.25) ($0.31) ($1.24) ($1.47) Shares used in calculation of basic and diluted net loss per share: 56,524 56,189 56,403 56,169 (1) Stock-based compensation expenses included in operating expenses amounted to approximately: Research and development $440 $560 $2,005 $3,005 Selling, general and administrative 790 899 3,397 4,758 Restructuring and impairment charges -- -- -- 968




                          IDENIX PHARMACEUTICALS, INC.

                     CONDENSED CONSOLIDATED BALANCE SHEETS

                                 (IN THOUSANDS)

                                   (UNAUDITED)

                                               December 31,     December 31,
                                                   2008             2007

    ASSETS
    Cash and cash equivalents                     $41,509          $48,260
    Marketable securities                           1,424           39,862
    Receivables from related party                    894           11,196
    Other current assets                            6,214            4,401
      Total current assets                         50,041          103,719
    Int
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... biologics ... cancer, CAMBRIDGE, Mass., June 10 Merrimack Pharmaceuticals,Inc., a ... for autoimmune disease and cancer, today announced that it,has raised ... Existing and new investors participated in the financing including,Credit Suisse ...
... BHRT ) today announced that it has received ... the Nasdaq Capital Market. The Company,s,common stock will be ... Market at the opening of business on Wednesday, June ... the Nasdaq Stock Market for,companies with a lower market ...
... June 10 Miltenyi Biotec has,acquired Medic Tools ... strengthens the portfolio in the area of sample,preparation. ... into the product range of instruments, reagents, and ... Boris Stoffel and,Franz G. Bucher, Vice President and ...
Cached Biology Technology:Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2Miltenyi Biotec GmbH Acquires Medic Tools AG 2
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with the ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Environmentalists are just as fond of talking about ... "sustainability" has become a buzzword. The problem is that ... have manifold interpretations. Agricultural scientists at the Technische Universitaet ... colleagues in theoretical and applied science they have managed ...
... viral polymerase may provide a new therapeutic target for host-adapted ... "Spread of Infection and Lymphocyte Depletion in Mice Depends on ... of the American Journal of Pathology . Highly ... strain of the influenza virus that has adapted to infect ...
... An innovative approach to brain research developed by ... School at Houston has been selected for funding ... designed to support high-impact, medical investigations. Valentin ... at the UT Medical School at Houston, has ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 2UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 3
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
... these culture chambers produce cell yields in ... range and are useful alternatives to multiple ... mechanical • strength and structural integrity • ... Certified nonpyrogenic and sterilized by gamma irradiation, ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
...
Biology Products: